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Abstract
There is strong evidence from human and animal models that exposure to maternal hyperglycemia during in utero
development can detrimentally affect fetal kidney development. Notwithstanding this knowledge, the precise effects of
diabetic pregnancy on the key processes of kidney development are unclear due to a paucity of studies and limitations in
previously used methodologies. The purpose of the present study was to elucidate the effects of hyperglycemia on ureteric
branching morphogenesis and nephrogenesis using unbiased techniques. Diabetes was induced in pregnant C57Bl/6J mice
using multiple doses of streptozotocin (STZ) on embryonic days (E) 6.5-8.5. Branching morphogenesis was quantified ex vivo
using Optical Projection Tomography, and nephrons were counted using unbiased stereology. Maternal hyperglycemia was
recognised from E12.5. At E14.5, offspring of diabetic mice demonstrated fetal growth restriction and a marked deficit in
ureteric tip number (control 283.7623.3 vs. STZ 153.2624.6, mean6SEM, p,0.01) and ureteric tree length (control
33.162.6 mm vs. STZ 17.662.7 mm, p= 0.001) vs. controls. At E18.5, fetal growth restriction was still present in offspring of
STZ dams and a deficit in nephron endowment was observed (control 1246.2664.9 vs. STZ 822.4674.0, p,0.001). Kidney
malformations in the form of duplex ureter and hydroureter were a common observation (26%) in embryos of diabetic
pregnancy compared with controls (0%). Maternal insulin treatment from E13.5 normalised maternal glycaemia but did not
normalise fetal weight nor prevent the nephron deficit. The detrimental effect of hyperglycemia on ureteric branching
morphogenesis and, in turn, nephron endowment in the growth-restricted fetus highlights the importance of glycemic
control in early gestation and during the initial stages of renal development.
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Introduction
The global prevalence of diabetes in pregnancy is increasing,
both in terms of gestational diabetes mellitus (first diagnosis of
diabetes in pregnancy) and pre-existing type 1 and 2 diabetes
mellitus [1,2]. Irrespective of the etiology of maternal diabetes, the
developing fetus is exposed to a hyperglycemic intrauterine
environment, which confers an increased risk of adverse perinatal
outcomes such as birth trauma, cesarean delivery and altered fetal
growth patterns [3,4]. Maternal insulin therapy can reduce the
likelihood of these adverse perinatal outcomes [5]. Offspring
exposed to intrauterine hyperglycemia also have an elevated risk of
developing congenital malformations [6,7,8], and moreover, have
an increased susceptibility to develop metabolic diseases in
adulthood [9,10,11].
Maternal hyperglycemia is also associated with altered offspring
kidney development. Although kidney development is a compli-
cated process, two key events in kidney development are ureteric
branching morphogenesis and nephrogenesis [12]. The kidney
arises by the outgrowth of the ureteric bud and branching of the
ureteric epithelium into a complex tree-like structure, which
ultimately forms the renal collecting duct system and calyces.
Nephrogenesis is induced only at the tips of the branching ureteric
epithelium highlighting the association between ureteric tip
number and nephron endowment. Of the congenital malforma-
tions observed in offspring of diabetic pregnancy, genitourinary
defects and renal malformations are prevalent [13,14,15]. Studies
of streptozotocin (STZ) induced type 1 diabetes mellitus (T1DM)
suggest that exposure to hyperglycemia can lead to reduced
nephron endowment [16,17,18]. However, studies are few and less
than optimal methods have been used to count glomeruli. While
nephron endowment is highly dependent on adequate ureteric
branching morphogenesis, to date the effect of hyperglycemia on
ureteric tree development has not been assessed in vivo. Until
recently, assessment of ureteric branching morphogenesis typically
involved culturing fetal kidneys for a number of days in vitro. This
procedure results in a flattened kidney that can be wholemount
immunostained and imaged. Previous in vitro culture studies have
been limited to measures of ureteric tip number and have
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produced inconsistent results [16,19,20]. These discrepancies are
likely the result of variability inherent to culture preparations,
differences in the length of culture time and the type of media and
supplements used. A better understanding of the effect of
hyperglycemia on ureteric branching morphogenesis, and in turn
nephrogenesis, is required.
To explore the effect of hyperglycemia on the developing kidney
we utilized unbiased techniques to determine the effect of maternal
diabetes on key processes of kidney development in the mouse.
Ureteric branching morphogenesis was quantified ex vivo using
Optical Projection Tomography (OPT) and nephron number was
estimated using the gold standard stereological method [21].
Insulin was administered to pregnant dams to determine if
glycemic control during a period of early nephrogenesis could
prevent a nephron deficit in offspring of diabetic pregnancy.
Results
STZ increases maternal blood glucose concentrations
from E12.5 leading to offspring growth restriction and
reduced ureteric tree development at E14.5
Maternal blood glucose concentrations did not differ between
control dams (n= 5) and STZ-treated dams (n= 5) before
pregnancy (p=0.50) or prior to STZ injections at E6.5 (p=0.88)
(Figure 1A). Maternal blood glucose concentrations were
significantly elevated post STZ injections at E12.5 (p,0.01) and
E14.5 (p,0.0001). Glucose area under the curve (AUC) was
greater in STZ-treated dams than in control dams across gestation
(control 168.8268.96 mmol/l.day vs. STZ 205.7664.99 mmol/
l.day p,0.01).
Figure 1. Maternal blood glucose concentrations and ureteric tree development in offspring of the E14.5 cohort. (A) 3 hour fasting
blood glucose concentration of control (solid line) and STZ-treated (dashed line) dams throughout gestation. (B) Rendered reconstructions of the
ureteric tree of control (left) and STZ-treated (right) embryos at E14.5. Scale bar denotes 200mm. Quantitative analysis of (C) ureteric branch points, (D)
branch tip number, (E) ureteric tree length, (F) ureteric tree volume and (G) branch segment length of control (clear bar) and STZ-treated (solid bar)
embryos. Glucose analysis by repeated measures two-way ANOVA for maternal STZ treatment and time followed by Fishers LSD post hoc analysis;
n = 5 dams/group. Ureteric tree analysis by two-way ANOVA for maternal STZ treatment and offspring sex followed by Fishers LSD post-hoc analysis;
n = 5 litters comprising 9 kidneys per group. Values are mean6SEM. *p,0.05, **p,0.01, ****p,0.0001 vs. control group.
doi:10.1371/journal.pone.0058243.g001
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Amniotic fluid of E14.5 STZ-treated embryos had a signifi-
cantly greater glucose concentration compared with that of control
embryos (control 7.1660.49 mmol/l vs. STZ 16.3061.49 mmol/
l, p,0.0001).
There was no difference in litter size (control 8.260.7 embryos
vs. STZ 8.660.4 embryos, p=0.62), viable embryos (control
8.260.7 embryos vs. STZ 6.660.5 embryos, p=0.09) or
resorptions (control 0.460.2 embryos vs. STZ 0.860.4 embryos,
p=0.40) between control and diabetic pregnancies at E14.5. Dead
embryos were absent in control pregnancies however 23% of
embryos of diabetic pregnancies were dead at collection.
Embryos of STZ-treated dams were 32% lighter in weight
(p,0.01), 12% smaller in crown-rump length (p,0.01) and 10%
smaller in head width (p=0.01) compared with control embryos at
E14.5 (Table 1). Embryos of diabetic dams were not develop-
mentally delayed, as assessed by Theiler staging. Placentas of STZ-
treated embryos were significantly lighter than placentas of control
embryos at E14.5 (75.4365.18 mg; 115.1965.09 mg, p=0.001).
While no treatment*sex interaction was found across growth
parameters, sex had a significant effect on growth with male
offspring exhibiting heavier bodyweights (p,0.01) and placental
weights (p=0.02) than females.
OPT demonstrated that the kidneys of E14.5 embryos exposed
to hyperglycemia were smaller than control kidneys and had a
significantly smaller ureteric tree (Figure 1B). Quantitative
analysis revealed that the kidneys of embryos exposed to
hyperglycemia contained 45% fewer ureteric branch points
(p=0.002; Figure 1C), 46% fewer ureteric tips (p=0.002;
Figure 1D), a 47% reduction in total ureteric tree length
(p=0.001; Figure 1E) and a 49% reduction in tree volume
(p=0.004; Figure 1F) compared with control kidneys. Kidneys of
STZ-treated embryos had on average fewer branch generations
than control kidneys (control 7.560.1 vs. STZ 6.760.2, p=0.001).
Compared with controls, STZ-treated kidneys had significantly
shorter branch segment lengths from branch generations five to
eight (5th generation, p=0.02; 6th generation, p=0.004; 7th
generation, p=0.008; 8th generation, p=0.02; Figure 1G).
Spearman’s rank coefficient revealed bodyweight, STZ treat-
ment and maternal glucose AUC to have strong associations with
measures of ureteric tree development at E14.5 (Table 2). In a
stepwise multiple regression model, fetal bodyweight, maternal
STZ treatment and maternal glucose AUC predicted branch point
number (R2= 0.87, p,0.0001), with bodyweight contributing the
most to the model (b=1.03, p,0.0001) above maternal STZ
treatment (b=0.29, p=0.17) and maternal glucose AUC
(b=20.18, p=0.29). When variables were considered indepen-
dently, fetal body weight was the only statistically significant factor
(R2 = 0.85, p,0.0001). Similar trends were observed for tip
number, tree length, tree volume and average branch generations.
Administration of insulin from E13.5 reduces maternal
blood glucose concentrations by E15.5 but does not
normalise fetal growth or nephron number
Similar to the E14.5 cohort, maternal blood glucose concen-
trations did not differ between control (n = 11) and STZ-treated
dams (n= 13) prior to pregnancy (p=0.91) or at E6.5 (p=0.29)
(Figure 2A). Blood glucose concentrations of STZ-treated dams
were significantly greater than control values at E12.5 (p=0.0002).
Blood glucose concentrations remained significantly higher in
STZ-treated dams (n = 8) at E15.5 (p,0.0001) and E18.5
(p,0.0001). The administration of insulin from E13.5 to STZ-
treated dams (n= 5) significantly reduced maternal blood glucose
levels to a concentration that was comparable to controls by E15.5
(p=0.21) and at E18.5 (p=0.93) (Figure2A). Maternal glucose
AUC was significantly different across all treatment groups
Table 1. Growth parameters of control and STZ-treated embryos at E14.5; and control, STZ and STZ+Insulin-treated embryos at
E18.5.
Bodyweight (mg)
Crown-Rump Length
(mm) Head width (mm) Placenta weight (mg)
E14.5 Control Male 280.3615.7 11.9 60.3 7.160.2 118.865.5
Female 261.1615.8 11.860.3 7.060.2 111.665.6
STZ Male 189.9615.9 10.560.3 6.460.2 79.965.7
Female 180.1 616.1 10.460.3 6.360.2 71.065.8
Ptreatment 0.004 0.004 0.01 0.001
Psex 0.008 0.32 0.58 0.02
Ptreatment*sex 0.38 0.87 0.63 0.79
E18.5 Control Male 1169.7632.0 20.960.5 10.860.2 112.665.5
Female 1184.4633.7 21.060.5 10.960.2 108.765.6
STZ Male 748.7637.8 16.860.5 9.360.2 72.966.3
Female 727.7640.3 16.660.6 9.460.2 61.467.0
STZ+Insulin Male 752.3648.9 17.060.7 10.060.3 80.368.3
Female 713.7655.4 16.260.8 9.660.3 69.769.0
Ptreatment ,0.0001 ,0.0001 ,0.0001 ,0.0001
Psex 0.54 0.12 0.50 0.04
Ptreatment*sex 0.61 0.19 0.27 0.62
Data from E14.5 and E18.5 cohorts were analysed separately by a linear mixed model with maternal STZ and insulin treatment and offspring sex as independent
variables, weighted for litter. Values are mean6SEM. E14.5: (n) = control (n = 5 litters comprising 41 embryos), STZ-treated (n = 5 litters comprising 33 embryos). E18.5:
(n) = control (n = 11 litters comprising 72 embryos), STZ (n = 10 litters comprising 41 embryos), STZ+Insulin (n = 5 litters comprising 25 embryos).
doi:10.1371/journal.pone.0058243.t001
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(control 198.8562.40 mmol/l.day; STZ 260.4868.87 mmol/
l.day; STZ+Insulin 229.5862.28 mmol/l.day, p,0.0001).
For the E18.5 cohort there was no difference in litter size across
the three treatment groups (control 6.760.8 embryos; STZ
4.560.8 embryos; STZ+insulin 5.460.9 embryos, p=0.13).
However post-hoc analysis indicated that litters from STZ-treated
dams had significantly fewer live embryos than control dams
(control 6.660.7 embryos; STZ 3.960.7 embryos, p=0.02). No
difference was detected in the number of resorptions (control
0.560.2 resorptions; STZ 1.960.6 resorptions; STZ+insulin
1.460.5 resorptions, p=0.055) or dead embryos (control
0.160.1 embryos; STZ 0.660.3 embryos; STZ+insulin 0.460.2
embryos, p=0.12) at E18.5.
Post-hoc analysis found embryos of STZ-treated dams were
37% lighter in weight (p,0.0001), 20% shorter in crown-rump
length (p,0.0001) and 14% shorter in head width (p,0.0001) than
control embryos at E18.5 (Table 1). Comparably, STZ+Insulin-
treated embryos were smaller than control embryos for weight
(38% lighter, p,0.0001), crown-rump length (21% shorter,
p,0.0001) and head width (10% shorter, p=0.004). Body weight,
crown-rump length and head width did not differ between STZ-
treated and STZ+Insulin-treated embryos. STZ-treated embryos
had a 39% lighter placental weight than control embryos
(p,0.0001). Placental weight of STZ+Insulin-treated embryos
was 32% lighter than control embryos (p=0.0007) and did not
differ to STZ-treated embryos (p=0.41). Sex was found to have
only a significant effect on placental weight, with males having
heavier placental weights than females (p=0.04) and there was no
treatment*sex interaction.
At E18.5, kidneys of STZ-exposed embryos had 34% fewer
nephrons than control kidneys (p=0.0007) (Figure 2B). Kidneys
of STZ+Insulin-treated embryos had 30% fewer nephrons than
control kidneys (p=0.003). Nephron number did not differ
between kidneys of STZ and STZ+Insulin-treated embryos
(p=0.67).
Spearman’s rank coefficient showed that fetal bodyweight,
maternal STZ and insulin treatment and maternal glucose AUC
had strong associations with glomerular number at E18.5
(Table 3). In a stepwise multiple regression model, fetal body-
weight, maternal STZ and insulin treatment and maternal glucose
AUC were found to predict glomerular number (R2 = 0.72,
p,0.0001), with fetal bodyweight contributing the most to the
model (b=0.93, p,0.0001) above that of maternal STZ and
insulin treatment (b=0.04, p=0.76) and maternal glucose AUC
(b=0.06, p=0.71). When variables were considered independent-
ly, fetal body weight was the only statistically significant factor
(R2 = 0.72, p,0.0001).
Malformations of the kidney and urinary tract in offspring
of diabetic dams
Interestingly, 26% of offspring of diabetic dams demonstrated
renal and urinary tract abnormalities. This was observed as duplex
ureter and duplicated collecting duct systems at E14.5 and E18.5
(Figures 3A–C), and with hydroureter at E18.5 (Figure 3D).
Renal malformations equally affected male and female embryos,
and were evident in both STZ and STZ+Insulin treated embryos.
No urinary tract malformations were observed in control offspring.
Discussion
This is the first study to apply an ex vivo method to analyse
development of the ureteric tree of embryos exposed to
hyperglycemia, and confirms branching morphogenesis is mark-
edly reduced in hyperglycemia. Our use of OPT and parameter-
isation of the ureteric tree has shown that kidneys of diabetic
pregnancy at E14.5 have approximately half the number of
ureteric tips and branch points, a reduced tree length and volume,
and fewer branch generations compared with controls. We also
report shorter branch segments for the middle branch generations
of STZ-treated kidneys, which may correspond to a cumulative
disruption in branching morphogenesis as maternal glucose
concentrations increase. While no difference in Theiler staging
was found between embryos of diabetic and control pregnancies it
is possible kidneys of STZ-diabetic embryos are developmentally
delayed. Ureteric tree development may resemble that of earlier
staged embryos and warrants further investigation.
Table 2. Spearman’s rank coefficients: associations between measures of ureteric tree development and independent variables at
E14.5.
Bodyweight Treatment Glucose AUC
Treatment 20.87
(p,0.01)
Glucose AUC 20.82 0.87
(p,0.01) (p,0.01)
Branch number 0.87 20.82 20.81
(p,0.01) (p,0.01) (p,0.01)
Tip number 0.87 20.82 20.81
(p,0.01) (p,0.01) (p,0.01)
Tree length 0.87 20.82 20.78
(p,0.01) (p,0.01) (p= 0.01)
Tree volume 0.87 20.82 20.78
(p,0.01) (p,0.01) (p= 0.01)
Average number of branch generations 0.84 20.76 20.72
(p,0.01) (p,0.01) (p,0.01)
Spearman’s Rho (top value), p value (bottom value). Negative values indicate a negative association. AUC = area under the curve.
doi:10.1371/journal.pone.0058243.t002
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Our findings regarding ureteric tree development support those
of Kanwar et al. [19] and Amri et al. [16] who reported branching
dysmorphogenesis and inhibition of ureteric arborisation in
metanephroi cultured in the presence of a high concentration of
glucose. In contrast, Zhang et al. [20] observed a stimulatory effect
of transient high glucose on ureteric branching in vitro. While
metanephric organ culture has proven a major research tool in
developmental nephrology, cultured kidneys are unnaturally
flattened, avascular and grow at a relatively slow rate; factors
which affect and distort ureteric branching morphogenesis
[22,23]. Inconsistencies between findings from previous studies
may be due to differences in media and length of culture time.
While it is plausible that short term exposure to high glucose may
stimulate branching as observed by Zhang et al. [20], extended
periods of exposure, as observed in the present study in diabetic
pregnancy, result in a different outcome. As this study and that of
Zhang et al. [20] are described in mice on the C57Bl6
background, discrepancies between the two are most likely
explained by differences in methodology (in vivo STZ-induced
diabetes in the dam vs. in vitro kidney explants cultured in high
glucose) rather than strain differences.
Our findings demonstrate that exposure to hyperglycemia leads
to a deficit in nephron endowment at E18.5 as assessed by an
unbiased stereological technique. The present study confirms the
findings of Amri et al. [16] and Tran et al. [17] who used the acid
maceration method and disector/fractionator technique, respec-
tively. Collectively we demonstrate that diabetic pregnancy
impairs nephrogenesis in proportion to the magnitude of maternal
glycemia. Deficits in nephron endowment in offspring of diabetic
pregnancy have been described across a range of species and
strains: Sprague Dawley rat (Amri et al. 1999), Wistar rat (Rocha
et al. 2005), Swiss mouse (Cunha et al. 2008) and Hoxb7-GFP
mouse on a C57Bl6 background (Tran et al. 2007). However the
findings of Cunha et al. [18] are perhaps questionable as they
observed no difference in nephron number between control and
STZ-treated mice after the completion of nephrogenesis at PN7
yet reported a 20% reduction at PN21.
We report altered kidney development in growth-restricted
offspring of diabetic pregnancy. Human maternal diabetes is
typically associated with infant macrosomia and elevated birth
weight. However, in a subset of women with severe hyperglyce-
mia, poorly controlled diabetes, vascular complications or
excessive insulin administration, intrauterine growth restriction is
a frequent observation [24,25,26,27]. In rodent models of diabetic
pregnancy, STZ is frequently used and depending on the degree of
hyperglycemia may lead to a range of alterations in offspring
Figure 2. Maternal blood glucose concentrations and glomerular number in offspring of E18.5 cohort. (A) 3 hour fasting blood glucose
concentrations of control (solid line, filled square), STZ-treated (dashed line, open square) and STZ+Insulin-treated (dashed line, open circle) dams
throughout gestation. (B) Total glomerular number in kidneys of control (clear bar), STZ-treated (striped bar) and STZ+Insulin-treated (solid bar)
embryos. Glucose analysis by repeated measures two-way ANOVA for maternal STZ and insulin treatment and time followed by Fishers LSD post hoc
analysis; (n) = control (11), STZ (8), STZ+Insulin (5). Glomerular number analysis by two-way ANOVA for maternal STZ and insulin treatment and
offspring sex followed by Fishers LSD post-hoc analysis; (n) = control (7 litters comprising 20 kidneys), STZ (6 litters comprising 14 kidneys),
STZ+Insulin (5 litters comprising 10 kidneys). Values are mean6SEM. **p,0.01, ***p,0.001 ****p,0.0001 vs. control.
doi:10.1371/journal.pone.0058243.g002
Table 3. Spearman’s rank coefficients: associations between
glomerular number and independent variables at E18.5.
Bodyweight Treatment Glucose AUC
Treatment 20.74
(p,0.001)
Glucose AUC 20.80 0.73
(p,0.001) (p,0.001)
Nglom 0.86 20.71 20.68
(p,0.001) (p,0.001) (p,0.001)
Spearman’s Rho (top value), p value (bottom value). Negative values indicate a
negative association. AUC = area under the curve. Nglom = total estimated
glomerular number.
doi:10.1371/journal.pone.0058243.t003
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growth. Both normal and large for gestational age pups
[16,28,29,30] have been observed in mildly diabetic dams,
however growth restriction is a common outcome in severely
hyperglycemic STZ-treated dams [17,31]. In the latter instance,
this is due to profound fetal hyperglycemia and hyperinsulinemia
associated with fetal pancreatic exhaustion. In the present study
STZ-treated dams exhibited severe fasting hyperglycemia and
their offspring were hyperglycemic (measured in amniotic fluid at
E14.5) and growth restricted. Kidney development in large for
gestational age offspring of diabetic pregnancy has yet to be
investigated. This may relate to the difficulty in obtaining
macrosomic pups in rodents where fat composition at birth is
low (2% fat) compared to humans (,15% fat). However,
considering the strong linear relationship we observed between
fetal growth and nephron endowment the effect of maternal
diabetes in macrosomic offspring would be of particular interest.
Despite restoring glucose levels to within the range of control dams
from E15.5, insulin treatment did not normalise fetal growth of
STZ+insulin treated dams. This may be due to the timing of
insulin treatment after hyperglycemia onset considering insulin
mini-pumps were implanted at E13.5, seven days after STZ
administration. Studies utilising immediate insulin treatment
following STZ administration, in contrast, report normal embryo
growth [32,33]. It is therefore likely that the persistent deficit in
nephron number at E18.5 observed in STZ+insulin exposed
embryos is related to the late instigation of glycemic control.
Embryos exposed to diabetes had a marked deficit in ureteric
branching morphogenesis at E14.5. As nephron induction occurs
at the site of nascent ureteric tips it is likely that a low nephron
number was already established prior to insulin treatment at
E13.5. Insulin was administered at this time point to determine if
the effect on the developing kidney is principally due to altered
branching morphogenesis (which largely occurred prior to
instigation of insulin treatment) or nephron induction/mainte-
nance (which primarily occurred post commencement of insulin
treatment). While we did not expect complete normalisation of
nephron endowment at E18.5 in this group, if the process of
nephrogenesis was indeed retarded by hyperglycemia then we
might predict that normalizing glycaemia would result in some
increase in the nephron endowment. As this was not observed, we
conclude that the process of branching morphogenesis was
severely affected giving rise to a deficit in ureteric tip number
and thus sites for nephron formation. An alternative explanation is
that insulin therapy was administered too late after diabetes
induction and late glycemic control, initiated past the time-point
when ureteric branching morphogenesis is at its peak, could not
restore these deficits. The hypothesis that impaired ureteric
branching is central to the nephron number deficit is supported
by Chen at el. [34] who found insulin treatment to partially
normalise nephron number in neonates of STZ-treated dams
where diabetes was induced later in gestation at E13 followed by
insulin implantation at E15. This protocol partially restored
Figure 3. Congenital abnormalities in offspring of mothers with diabetes. (A, B) Rendered OPT images of duplex ureter at E14.5. Note that
each ureter is associated with a separate region of the ureteric tree. (C) Duplex ureter at E18.5 compared with control kidney on the left. (D)
Hydroureter at E18.5. Scale bar denotes 200 mm.
doi:10.1371/journal.pone.0058243.g003
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maternal blood glucose concentrations from a 5-fold to 2.5-fold
elevation compared with controls, normalised neonatal body-
weight to within control values and reduced the nephron deficit by
half [34,35].
Infants of gestational diabetic and overt diabetic pregnancies
have an elevated risk of anomalies of the urinary tract [14,36,37].
We observed malformations of the urinary tract in embryos of
diabetic pregnancy, further suggesting that early ureteric branch-
ing morphogenesis and possibly ureteric budding are primary
processes targeted in hyperglycemia. These abnormalities included
duplex ureters and hydroureter. Together the findings highlight
that the longer the window of exposure to diabetes the more
adverse the consequences are to fetal and renal development, yet
may also indicate that hyperglycemia exposure during specific,
shorter windows of development (i.e. when branching of the
ureteric tree is maximal) may also be detrimental to kidney
development.
The effects of STZ treatment in this study are ascribed to
changes in maternal pancreatic function, but direct effects of STZ
on the fetus should also be considered. Previously, the addition of
STZ (1 mg/ml) to cultured rat embryos was found to reduce their
viability and growth (Deucher et al. 1977). This dose was
administered to reflect the dose given to an adult rat to induce
diabetes and likely does not reflect the level of STZ the fetus is
exposed to in vivo. In the rhesus monkey, STZ has been reported to
cross the placenta with relatively low concentrations reaching the
fetus (Reynolds et al. 1974), but data for rodents is lacking. While
we cannot rule out the secondary effects of STZ on fetal growth,
given the short half-life of STZ (,15 min) and the small volumes
reaching the fetus we believe it is unlikely that STZ exerts a toxic
effect on the fetus. This can be further extended to the developing
kidney. Tran et al (2008) examined kidney size and the number of
glomeruli in fetuses of STZ-exposed dams that went on to develop
or not develop diabetes. They found renal damage to be
independent of STZ administration or length of STZ exposure
but attributable to the level of maternal hyperglycemia. This
finding is supported by Amri et al. (1999) who reported a
comparable nephron deficit in offspring of a glucose infusion
model in the pregnant rat and in offspring of STZ-induced
diabetes. STZ has a serum half-life of 15 minutes [38] and
following STZ treatment at E6.5, E7.5 and E8.5 in the present
protocol it is expected to be cleared from the maternal circulation
before fetal metanephric development commences at E10.5.
In our model of growth restriction in diabetic pregnancy it is
difficult to discriminate the effect between low birth weight and
high glucose as the driving force of altered kidney development.
Regression analysis identified fetal growth as the strongest
predictor of kidney development in diabetic pregnancy, and is
consistent with published literature. Human studies have identified
a strong linear relationship between birth weight and nephron
number [39,40,41]. Animal models of spontaneous [42,43] and
induced growth restriction [42,44,45] further support this associ-
ation. In rodents, high glucose exposure is reported to alter kidney
morphology and lead to a nephron deficit in growth restricted and
normal birth weight offspring [16,17]. The direct effect of high
glucose on the kidney has been linked to aberrant Pax-2, NF-kb
and p53 signaling pathways, nascent nephron apoptosis [17,34]
and the altered expression of extracellular matrix glycoproteins
[46]; processes mediated by elevated reactive oxygen species
(ROS) generation. While infants of diabetic pregnancy have an
increased risk of renal and urinary tract malformations [15,36,37],
less severe outcomes such as altered nephron endowment in
persons exposed to intrauterine hyperglycemia have not been
described.
Pregnant women are typically not screened for diabetes until
28-30 weeks gestation. As kidney development begins at 5 weeks
gestation with the full complement of nephrons reached by 36
weeks, the developing fetal kidney may be unknowingly exposed to
a lengthy window of hyperglycemia. Impaired kidney development
may therefore already be established and pharmacological
interventions such as insulin therapy could have limited potential
to mediate fetal kidney development, if the outcomes of this study
are transferrable to humans. Impaired kidney development (by
altered ureteric branching morphogenesis, nephrogenesis, or both)
may lead to a permanent nephron deficit and a predisposition to
hypertension and chronic renal disease, a hypothesis first
enunciated by Brenner and colleagues [47]. While offspring were
not followed into adulthood, we can predict that offspring may
display a range of long-term metabolic defects as reported in a
small number of animal [28,35,48] and human studies [49,50,51].
In conclusion, we report ureteric branching morphogenesis and
nephrogenesis to be adversely affected in offspring exposed to
STZ-induced diabetic pregnancy. We present the first study to
examine ex vivo and in 3D the ureteric tree of embryos of diabetic
pregnancy, and report a marked deficit in ureteric branching
morphogenesis. We hypothesize that this early alteration in
ureteric tree architecture gives rise to the nephron deficit observed
in late gestation. Glycemic control which normalized maternal
glucose levels to that of control values did not prevent embryo
growth restriction or a nephron deficit prior to birth, and
highlights the detrimental effect of hyperglycemia in pregnancy
on kidney development. This suggests that late insulin therapy
would not be useful in preventing aberrant kidney growth. This is
particularly important for women identified with diabetes
relatively late in gestation as kidney development is well underway,
and potentially irreversible deficits in branching morphogenesis
and nephrogenesis may be established. This adds impetus to the
importance of vigilant glucose monitoring throughout pregnancy
as it may set the scene for poor kidney health and long-term
consequences in the offspring.
Materials and Methods
Animals
Experimentation was performed on 8-12 week old C57BL/6J
mice (Monash Animal Services, Victoria, Australia). All animal
handling and experimental protocols were approved by the
Animal Ethics Committee of Monash University (SOBS A/
2010/07) and conformed to the guidelines of the National Health
and Medical Research Council of Australia. Mice had ad libitum
access to standard chow and water with a 12 hour light/dark
cycle. Mice were mated overnight. The presence of a vaginal plug
the following morning indicated embryonic day 0.5 (E0.5).
Diabetes Induction
Maternal diabetes was induced by the intraperitoneal admin-
istration of streptozotocin (STZ) (Sigma-Aldrich, Castle Hill,
Australia) in 0.1 M sodium citrate buffer. STZ was administered
for 3 consecutive days commencing at E6.5 at doses of 100, 100
and 80 mg/g bodyweight. Control mice received intraperitoneal
injections of 0.1 M sodium citrate buffer for 3 days from E6.5.
Maternal blood glucose concentration (mmol/l) was measured
prior to mating and throughout pregnancy by cheek bleed
following a 3 hour fast (Accu-Chek Go Blood Glucose Monitor,
Roche Products, Dee Why, NSW, Australia). The glucose
concentration of amniotic fluid at E14.5 was measured on the
same glucometer. Maternal glucose concentrations across gesta-
tion were estimated by plotting glucose concentrations (mmol/l)
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against time (days) and quantifying the area under the curve
(AUC, mmol/l.day).
Insulin Treatment
A proportion of hyperglycemic dams received insulin to form a
glycemic control group (n= 5). Dams at E13.5 were surgically
implanted under isoflurane anesthesia with an osmotic mini-pump
(model 1007D, Alzet, Durect Co., Cupertino, CA, USA) filled with
NovoRapid insulin aspart (100 U/ml, Novo Nordisk, Baulkham
Hill, NSW, Australia) at a 1:10 dilution in saline with an infusion
dose of 0.5 ml/hr. Control animals underwent sham surgery that
followed the protocol as outlined above bar the implantation of the
mini-pump (n= 4). Tissue was collected at E18.5 for animals in the
glycemic control group.
Tissue Collection
Pregnant mice were dissected at E14.5 and E18.5 to form two
separate cohorts. Embryo development was verified by Theiler
staging criteria [52]. Embryos and placentas were weighed and
measures of crown-rump length and head diameter recorded with
digital micro-calipers. Embryos were sexed (based on gonad
appearance) and metanephroi removed and fixed in 4% parafor-
maldehyde (PFA) in phosphate buffered saline (PBS) (Sigma-
Aldrich, Castle Hill, NSW, Australia).
Analysis of Ureteric Tree Development: Optical Projection
Tomography
The ureteric epithelium of E14.5 kidneys was wholemount
fluorescently immunostained, optically cleared and imaged by
OPT as based on the protocol of Short and Smyth [53].
Metanephroi were transferred to methanol and subject to 3
freeze-thaw cycles to assist antigen retrieval [54]. Kidneys were
rehydrated, blocked, and incubated in E-cadherin primary
antibody (1:100 dilution, rat E-cadherin monoclonal antibody;
Invitrogen, Mulgrave, VIC, Australia). Kidneys were washed and
then incubated in secondary antibody (1:400 dilution, Alexa Fluor
555 goat anti-rat IgG; Invitrogen, Mulgrave, VIC, Australia).
Stained E14.5 kidneys were embedded in 1% low melting point
agarose, dehydrated in methanol and cleared in benzyl alcohol/
benzyl benzoate (1:2 mixture) (Sigma-Aldrich, Castle Hill, NSW,
Australia). Immunostained kidneys were imaged in a Bioptonics
3001 OPT scanner and OPT tomographic data were reconstruct-
ed using N-Recon software (SkyScan, Kontich, Belgium). Drishti
software (v2.0, Australian National University, ANUSF VizLab,
Canberra, ACT, Australia) was used to visualise and render
reconstructed 3D data sets (see provided Supplementary Informa-
tion Video S1).
Quantitative assessment of the ureteric tree was performed
using Tree Surveyor software (version 1.0.8.20 [55]) from which
branch point number, ureteric tip number, tree length and tree
volume were automatically obtained. Kidneys with duplex ureters
and collecting duct systems were excluded from analysis.
Estimation of Glomerular Number: Histochemistry and
Stereology
Total glomerular number was determined using an unbiased
stereological method as previously described [21]. Briefly,
metanephroi were embedded in paraffin and exhaustively
sectioned at 5 mm. 10 evenly spaced section pairs were system-
atically sampled and histochemically stained with the lectin peanut
agglutinin (PNA) to localise the plasma membrane of glomerular
podocytes. Sections were counterstained with hematoxylin.
Section pairs were used to estimate PNA-positive developing
nephrons using the physical disector/fractionator combination
[21]. Kidneys with duplex ureter and hydroureter were excluded
from analysis.
Statistical Analysis
Data were analysed using SPSS (version 19, SPSS Inc., USA)
and GraphPad Prism (version 5, GraphPad Software, Inc., USA).
Glucose levels were analysed by two-way repeated measures
ANOVA with maternal STZ and insulin treatment and time as
main effects, followed by Fishers LSD post hoc analysis. Litter size
was analysed by independent samples t-test at E14.5 and one-way
ANOVA at E18.5. Measures of embryo growth and kidney
development were analysed by a two-way repeated measures
ANOVA for maternal STZ and insulin treatment and offspring
sex as main effects, and incorporating a mixed linear model to
account for any intra-litter bias [56]. Spearman’s rank co-efficient
with Bonferroni correction was used to measure associations
between kidney development and independent variables of interest
(fetal weight, maternal STZ and insulin treatment, maternal
glucose AUC and offspring sex). Spearman’s rank coefficient and
multiple regression analysis were performed using STATA
(version 8.0, Stata Corporation, USA). Throughout the paper n
refers to the number of dams or litters and not the total number of
pups. No difference in growth or kidney development was found
between control and control-sham embryos at E18.5 therefore the
two groups have been pooled to conserve power. Offspring sex was
incorporated as a variable in all analyses and had no statistically
significant effect unless otherwise stated. Data are presented as
mean 6 standard error of the mean (SEM). p,0.05 was
considered statistically significant.
Supporting Information
Video S1 Reconstructed 3D data set of E15 mouse
kidney.
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